The gig is up.

Outcomes at 7 years from the PCS5 trial show noninferior overall survival, prostate cancer mortality, and biochemical recurrence when using 68 Gy in 25 fractions versus 76 Gy in 38 fractions for high risk prostate cancer receiving 24 months of ADT. | Niazi, ASTRO 2022